Reps. Earl Blumenauer, D-Ore., and Ginny Brown-Waite, R-Fla., introduce July 30 the Tax Equity for Meal Replacements and Supplements Act of 2009. H.R. 3406 would exclude from employees' gross income employer-funded reimbursements of nutritional purchases with eligible health claims. In a release, Blumenauer said supplements can significantly improve health, and the measure can save money and reduce unnecessary doctor visits. The legislation follows a similar, broader bill introduced by Indiana Republican Rep. Dan Burton (1"The Tan Sheet" July 27, 2009). ... Tax advantages for infant formula: Health flexible spending arrangements could reimburse formula purchases for mothers with mastectomies who are medically unable to breastfeed, as part of H.R. 3445, introduced July 31 by Rep. Debbie Wasserman Schultz, D-Fla
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
